The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of time to neoadjuvant treatment initiation (TTI) for resectable non-small cell lung cancer (NSCLC) on clinical outcomes.
 
Srinidhi Radhakrishnan
No Relationships to Disclose
 
Olga Goloubeva
No Relationships to Disclose
 
William Wooten
No Relationships to Disclose
 
Katherine Scilla
Honoraria - OncLive/MJH Life Sciences
Research Funding - AstraZeneca (Inst); Merck (Inst); Teligene (Inst); Turning Point Therapeutics (Inst)
 
Ranee Mehra
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Coherus Biosciences; Janssen Oncology; Merck KGaA
Research Funding - AstraZeneca; Merck
Travel, Accommodations, Expenses - Merck KGaA
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Samuel Rosner
Honoraria - ASCO; Axiom Healthcare Strategies; Cardinal Health; DAVA Pharmaceuticals; EmPartners; Fenix Group International; MJH Healthcare Holdings, LLC
Consulting or Advisory Role - AstraZeneca; Regeneron
Research Funding - AstraZeneca (Inst); Conquer Cancer, the ASCO Foundation; Teligene (Inst)
Travel, Accommodations, Expenses - OncLive/MJH Life Sciences; Regeneron